Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by GObabyGO1on May 05, 2020 7:51pm
194 Views
Post# 30990562

RE:My Position

RE:My PositionI agree with you that the potential that this ends horrendously here is very real. My personal guess is 60% it works 40% it fails in human trials. Might as well call it 50/50. The positive animal trials give it the edge for me but anything can happen. You have to be ready for anything. The reality is once the Korean trial starts and news starts to flow that could launch or sink us. The other trials might not even matter. Negative news about this not being effective for COVID treatment and this goes to $0.10 quicky. Yes it has potential for chronic cough and all that but most investors are here for COVID. Let's be honest.
Management knows full well that this could crash and burn so they are cashing out with this PP. In my opinion they got greedy and screwed the current shareholders so they could grab an extra million from the original PP. Take the 6 Million just before trials start and see where this goes. All goes well they are filthy rich and this drug helps people all around the world that are suffering. It fails, meh doesn't matter, money in the bank on to the next one. Rinse and repeat. Indeed there will be lots of news releases going forward (hopefully not haulting for all of them ;)). The question is will it push this into dollars or cents? 
Regarding funding from the Canadian government, I think they are waiting to see how trials start and then they will pump money in once they see there is promise. Why would they throw money into something they have no idea will work or not. It's still very early. So many companies running trials and selling tests they can't fund everyone. The cream will rise to the top in the end. 
Bullboard Posts